Journal
CURRENT ONCOLOGY REPORTS
Volume 13, Issue 1, Pages 17-25Publisher
SPRINGER
DOI: 10.1007/s11912-010-0137-9
Keywords
Tissue biopsy; Metastases; Breast cancer; Estrogen receptor; ER; Progesterone receptor; PgR; Human epidermal growth factor receptor-2; HER2
Categories
Ask authors/readers for more resources
Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profiles (ER/PR and HER2) of primary and metastatic breast cancer is well documented. Whether discordant cases are secondary to clonal selection in the face of targeted anti-estrogen or anti-HER2 therapy or whether they are a laboratory artifact is still debated; both scenarios are likely. This article outlines current modalities for ER, PR, and HER2 testing in primary breast carcinoma and its metastases and reviews prospective and retrospective studies that have addressed these issues, as well as recent advances in the field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available